Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports new trial data for dapagliflozin

Bristol-Myers Squibb reports new trial data for dapagliflozin

27th September 2010

Bristol-Myers Squibb has published new phase III clinical trial data which underlines the efficacy of its investigational type 2 diabetes drug dapagliflozin.

The treatment was trialled in combination with metformin among 814 adult patients over a 52-week period, in order to compare the efficacy of the therapy with a regimen of glipizide plus metformin.

It was found that the dapagliflozin-based treatment was non-inferior in improving glycosylated haemoglobin levels, while providing superior performance in terms of reducing body weight.

Dr Michael Nauck, head of the Diabetes Center in Bad Lauterberg and lead investigator of the study, said the results represent positive news for diabetes patients, who often suffer from comorbidities alongside their blood sugar problems.

He added: "We are pleased to see the results from this phase III study found that dapagliflozin plus metformin compared favourably to glipizide plus metformin."

This comes in the same month that Bristol-Myers Squibb and development partner AstraZeneca announced further dapagliflozin trial results, demonstrating its advantages compared to glimepiride.ADNFCR-8000103-ID-800083270-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.